Related Experiment Video
Updated: May 31, 2026
07:00
A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
Published on: April 1, 2019
Progress of antiplatelet pharmacogenomics
1University of Nebraska Medical Center, Department of Pharmacy Practice, College of Pharmacy, Omaha, NE 68198-6045, USA. joestreich@unmc.edu
Current Drug Targets
|July 2, 2011
Summary
Genetic variants impact antiplatelet drug response. The CYP2C19*2 allele is linked to reduced clopidogrel effectiveness, but more research is needed before widespread genetic testing is recommended.
Area of Science:
- Pharmacogenomics
- Cardiovascular Medicine
- Clinical Genetics
Background:
- Genetic variations influence patient response to antiplatelet medications like aspirin and clopidogrel.
- Most studied variants lack clinical validity, but CYP2C19*2 shows a consistent association with altered drug metabolism.
Purpose of the Study:
- To review the evidence surrounding genetic variants and their impact on antiplatelet drug responsiveness.
- To evaluate the clinical validity and utility of genetic testing for guiding antiplatelet therapy, specifically clopidogrel.
Main Methods:
- Systematic review of studies investigating genetic polymorphisms and antiplatelet therapy response.
- Analysis of data correlating CYP2C19*2 allele status with platelet reactivity and clinical outcomes.
Main Results:
- The CYP2C19*2 allele is significantly associated with decreased clopidogrel responsiveness.
- Platelet reactivity testing and clinical outcomes data support the link between CYP2C19*2 carriers and reduced drug efficacy.
Conclusions:
- The FDA acknowledges the CYP2C19*2 allele's impact, suggesting treatment modification based on genotype.
- Further studies are required to establish the clinical utility of routine genetic testing for clopidogrel therapy.
Related Concept Videos
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:29Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...